ADC Development: Keys to Rapid IND Submission & Approval
When: August 10, 2017 11:00am CST
Antibody Drug Conjugates (ADCs) are a growing segment of the biopharmaceutical pipeline with currently dozens of ADCs in clinical trials and an estimated 150 in pre-clinical development. ADCs consist of a payload (toxin) covalently linked to a targeting sub-unit (monoclonal antibody). The vast majority of ADCs are utilized for the treatment of solid and hematological cancers. The antibody sub-unit binds to the cancer cell surface and the ADC is internalized to the cell cytoplasm. The endosome fuses with lysosomes resulting in cleavage of the linker, release of the free cytotoxin and cell death.